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S U M M A R Y
Background: The use of linezolid has increased with the emergence of multidrug-resistant bacteria.
Serum lactic acidosis has been reported as a serious side effect of linezolid use, therefore we evaluated
the incidence and characteristics of linezolid-related lactic acidosis.
Methods: Patients admitted to an 860-bed university hospital were enrolled. The patients were divided
into two groups, those who used linezolid and those who used teicoplanin (control group). The study was
conducted by review of the medical charts.
Results: Seventy-two patients were included in the linezolid group. The control group comprised
72 patients matched to those in the linezolid group for age and indication for antibiotic use. Lactic
acidosis occurred in ﬁve cases (6.8%) in the linezolid group. None of the patients who used teicoplanin
developed lactic acidosis, which was a comparable result. The median change in anion gap in the
linezolid group was 0.8 mmol/l (interquartile range (IQR) 3.55 to 1.28 mmol/l), which was
signiﬁcantly higher than in the teicoplanin group, 0.05 mmol/l (IQR 1.75 to 2.3 mmol/l) (p = 0.026). The
number of increased anion gap events in patients who used linezolid for more than 6 weeks was higher
than in the group who used linezolid for less than 6 weeks (p = 0.0014). However, no statistically
signiﬁcant difference was observed according to age, estimated glomerular ﬁltration rate, or diabetes.
Conclusions: Linezolid showed an association with treatment-related lactic acidosis. A longer duration of
linezolid use (>6 weeks) was one of the risk factors for metabolic acidosis. We suggest checking serum
lactate concentrations regularly, especially in those on long-term use.
 2015 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Linezolid (LZD), an antibiotic of the oxazolidinone class, has
activity against most Gram-positive bacteria. LZD is used in the
treatment of multidrug-resistant (MDR) Gram-positive bacteria,
such as vancomycin-resistant Staphylococcus aureus (VRSA) and
vancomycin-resistant Enterococcus (VRE), as an alternative
therapy for patients suffering from the side effects of glycopep-
tides, and for the treatment of MDR tuberculosis. In addition, the
use of LZD is increasing due to the emergence of prosthetic
infections in the elderly and an elevation of the vancomycin
minimum inhibitory concentration (MIC).
LZD-induced lactic acidosis was ﬁrst reported by Apodaca and
Rakita in 2003.1 LZD-induced lactic acidosis can occur as a serious
problem, resulting in death and multi-organ failure. However,
most people are not considered as having LZD-induced lactic* Corresponding author. Tel.: +82 32 890 2548; fax: +82 32 890 2549.
E-mail address: ljinsoo@inha.ac.kr (J.-S. Lee).
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1201-9712/ 2015 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/3.0/).acidosis, and there are no data on the incidence and risk factors of
LZD-induced lactic acidosis. Therefore, we evaluated the incidence
and characteristics of LZD-related lactic acidosis.
2. Materials and methods
2.1. Case identiﬁcation and study population
Patients admitted to an 860-bed university hospital from April
2003 to July 2012 were enrolled. They received either oral or
intravenous antibiotic administration. Patients were divided into
two groups: those who used LZD and those who used teicoplanin
(control group). The two groups were matched for age (within
5 years) and the indications for antibiotic use. The study was
conducted by retrospective review of the medical charts.
Demographic data, underlying diseases, duration of antibiotic
use, and the results of laboratory examinations were analyzed.
Patients who developed hypoxia (n = 11), sepsis (n = 3), acute
blood loss (n = 2), diabetic ketoacidosis (n = 1), and progression ofious Diseases. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Clinical characteristics of patients at the time that the prescriptions for the study
antibiotics were ﬁlled
Characteristics Teicoplanin Linezolid
Prescriptions, n 72 72
Age, years, mean  SD 59.19  19.3 61.4  17.0
Female, n (%) 38 (52.8%) 39 (54.1%)
Reason for antibiotic use, n (%)
Skin and soft tissue infectiona 40 (55.6%) 40 (55.6%)
Pneumonia 7 (9.7%) 7 (9.7%)
Bacteremia and CRBSI 11 (15.3%) 11 (15.3%)
Intra-abdominal infection 3 (4.2%) 3 (4.2%)
Other infectionb 11 (15.3%) 11 (15.3%)
Coexisting conditions, n (%)
Diabetes mellitus 13 (18.0%) 20 (27.8%)
Chronic liver diseasec 2 (2.8%) 3 (4.2%)
Duration of antibiotic use,
days, median (IQR)
13.00 (7.0–21.7) 14.95 (13.6–17.0)
Duration of hospitalization,
days, median (IQR)
15.65 (14.1–17.4) 14 (8.0–24.0)
Initial chemistry
White blood cell count,  109/l 8.1 6.2 8.0  7.6
Hemoglobin, g/dl 10.3  1.4 10.1  1.4
Platelet count,  109/l 244.2  139.7 213.4  138.3
Blood urea nitrogen, mg/dl 20.7  17.6 25.2  23.9
Creatinine, mg/dl 1.3  1.1 1.3  1.0
eGFR, ml/min/1.73 m2 d 82.0  53.1 86.0  56.2
Sodium, mEq/l 134.5  4.8 137.5  4.8
Potassium, mEq/l 3.9  0.7 3.8  0.6
HCO3, mmol/l 24.0  4.3 23.6  3.9
Anion gap, mmol/l 15.35 (14.05–17.40) 14.95 (13.62–17.00)
SD, standard deviation; CRBSI, catheter-related blood stream infection; IQR,
interquartile range; eGFR, estimated glomerular ﬁltration rate.
a Skin and soft tissue infection: cellulitis, necrotizing fasciitis, myositis,
osteomyelitis, prosthetics joint infection, postoperative infection.
b Other infection: urinary tract infection, vascular infection, neutropenic fever,
endocarditis.
c Chronic liver disease: liver cirrhosis, hepatocellular carcinoma.
d Modiﬁcation of Diet in Renal Disease (MDRD) equation.
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could not be obtained (n = 20) were excluded.
2.2. Deﬁnition of lactic acidosis
‘Deﬁnite’ lactic acidosis was deﬁned as a serum pH of <7.25 and
serum lactate >4 mmol/l. ‘Probable’ lactic acidosis was deﬁned in
the case where metabolic acidosis was conﬁrmed but serum
lactate was unidentiﬁed, or where elevated serum lactate was
conﬁrmed but serum pH was unidentiﬁed. Lactic acidosis by drug
was in accordance with the probable grade of the Naranjo criteria
for adverse drug reactions.2
2.3. Data analysis
If lactic acid and arterial pH data were available, lactic acidosis
was evaluated directly; if there were no data, it was evaluatedTable 2
Anion gap and incidence of lactic acidosis after antibiotic use
Teicoplanin 
Post-antibiotic anion gap, mmol/l, median (IQR) 15.25 (14.10 t
Change in the anion gap, mmol/la, median (IQR) 0.05 (2.30 t
‘Deﬁnite’ lactic acidosisb, n 0 
‘Probable’ lactic acidosisc, n 0 
‘Deﬁnite’ + ‘probable’ lactic acidosis, n 0 
a Change in anion gap = (the end-point anion gap) – (the initial anion gap).
b ‘Deﬁnite’ lactic acidosis: lactic acid above 4 mEq and acidosis of below pH 7.25.
c ‘Probable’ lactic acidosis: lactic acid above 4 mEq or acidosis of below pH 7.25.
d Signiﬁcant difference.indirectly by anion gap. The anion gap was calculated using the
formula ([Na+] + [K+])  ([Cl] + [HCO3]). The baseline result was
that obtained prior to starting LZD, and the end-point result was
that obtained when LZD was stopped. The change in anion gap was
deﬁned as the difference between the initial anion gap and the
end-point anion gap. If there was no laboratory data on the day of
initiation or termination of LZD and teicoplanin, the ﬁrst result
after starting the drug or the last result before stopping the drug
was used. In such cases, the duration of antibiotic use was deﬁned
as ceasing at the day of the last result. For the subgroup analysis,
we used the change in the anion gap or the number of increased
anion gap events. An increased anion gap event was deﬁned as a
change in anion gap >4 mmol/l. When expressing the anion gap
and duration of antibiotic use, medians and interquartile ranges
(IQR) were reported because the Shapiro–Wilk test showed that
the outcome measures did not have a normal distribution. The Chi-
square test was used for the comparison of lactic acidosis incidence
between groups. Fisher’s exact test or the Mann–Whitney U-test
was used for comparisons of subgroups. The duration of antibiotic
use was analyzed by minimal p-value approach for cut-off
optimization. Two tailed p-values of <0.05 were considered
statistically signiﬁcant. The data analysis was performed using
SPSS statistical software version 18 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. General characteristics
Seventy-two patients were included in the LZD group and
72 patients who used teicoplanin, matched to the LZD group for
age and indication for antibiotic use, were included in the control
group. Underlying diseases were skin and soft tissue infection
(55.6%), bacteremia and catheter-related blood stream infection
(15.3%), pneumonia (9.7%), intra-abdominal infection (4.2%), and
other infections (15.3%).
The mean patient age was 61.4  17 years in the LZD group and
59.2  19.3 years in the teicoplanin group. The median duration
of antibiotic use was 19.7  18 days in the LZD group and
19.4  21.5 days in the teicoplanin group.
No signiﬁcant differences in demographic characteristics were
noted between the LZD and control groups (sex, initial white blood
cell (WBC) count, anion gap, estimated glomerular ﬁltration rate
(eGFR)) (Table 1).
The median duration of hospitalization for the LZD group was
14 days (IQR 8.00–24.00 days), which was shorter than that of the
teicoplanin group, 15.65 days (IQR 14.05–17.40 days). However,
considering that neither drug is generally used as a ﬁrst-line drug
and that there was no signiﬁcant difference in initial WBC count,
hemoglobin, creatinine, sodium, potassium, or HCO3 between the
two groups, there was no considerable difference in disease
severity.Linezolid p-Value
o 16.98) 16.4 (13.80 to 18.05)
o 1.75) 0.8 (1.28 to 3.55) 0.026d
2 0.154
3 0.080
5 0.023d
Table 3
Cases of linezolid-induced lactic acidosis
Age, years Sex Comorbidities Disease Kidney Chronic
liver
disease
Duration
of LZD
Variation in
anion gap
Peak
lactic
acid
pH Treatment Outcome
‘Deﬁnite’ Case 1 64 M Diabetes Soft tissue infection AKI None 7 weeks 26.6 20 6.91 HD Died
‘Deﬁnite’ Case 2 77 M Diabetes Prosthetic infection CKD None 4 weeks 20.9 16 7.1 HD Died
‘Probable’ Case 1 52 F Cancer Urinary tract infection Normal None 1 week 6.2 NR 7.19 Bivone Survived
‘Probable’ Case 2 76 M Diabetes Soft tissue infection AKI None 1 week 3.0 4.5 None None Survived
‘Probable’ Case 3 69 F Diabetes Prosthetic infection CKD None 5 weeks 4.0 4.8 None None Survived
LZD, linezolid; M, male; F, female; AKI, acute kidney injury; CKD, chronic kidney disease; NR, not reported; HD, hemodialysis.
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‘Deﬁnite’ lactic acidosis occurred in two cases (2.7%) and
‘probable’ lactic acidosis occurred in three cases (4.1%) (Supple-
mentary Material 1, Tables 2 and 3). None of the patients in the
group who used teicoplanin developed lactic acidosis, which was a
comparable result. Among the patients in the LZD group, two with
lactic acidosis died (Table 3).
3.3. Changes in anion gap: (anion gap after antibiotic use) – (initial
anion gap)
The median change in anion gap in the LZD group was
0.8 mmol/l (IQR 1.28 to 3.55 mmol/l), which was signiﬁcantly
higher than that in the teicoplanin group, 0.05 mmol/l (IQR 2.3
to 1.75 mmol/l) (p = 0.026, by Mann–Whitney U-test). We
evaluated the risk of a LZD-induced increasing anion gap by
subgroup analysis (Table 4). The change in anion gap was
4.20 mmol/l (IQR 0.20–20.9 mmol/l) in the patients who used
LZD for more than 6 weeks (n = 7), which was higher than that in
the patients who used LZD for 6 weeks (n = 65), 0.20 mmol/l (IQR
1.60 to 3.15 mmol/l). However there were no signiﬁcant
differences (false discovery rate (FDR) corrected, p = 0.349). The
number of increased anion gap events (a change in anion gap >4
mmol/l) was three in those who used LZD for >6 weeks (n = 7) and
two in those who used LZD for 6 weeks (n = 65) (p = 0.0014).
There was no statistically signiﬁcant difference in initial blood
chemistry between those using LZD for >6 weeks and those using
LZD for 6 weeks (Supplementary Material 2). Further, there
was also no difference between the group using teicoplanin forTable 4
Analysis of the linezolid subgroup
No. Eventsa p-Value
None, n (%) Yes, n (%)
Renal failure, eGFR, ml/min/1.73 m2
50 22 19 (28.4) 3 (60.0) 0.163
>50 50 48 (71.6) 2 (40.0)
Diabetes
Yes 20 50 (74.6) 2 (40.0) 0.127
No 52 17 (25.4) 3 (60.0)
Age, years
70 47 43 (64.2) 4 (80.0) 0.652
>70 25 24 (35.8) 1 (20.0)
Duration of antibiotic use, weeks
2 38 37 (55.2) 1 (20.0) 0.728
>2 34 30 (44.8) 4 (80.0)
4 57 55 (82.1) 2 (40.0) 0.227
>4 15 12 (17.9) 3 (60.0)
6 65 63 (96.0) 2 (40.0) 0.0014b
>6 7 4 (6.0) 3 (60.0)
eGFR, estimated glomerular ﬁltration rate.
a Event = a change in anion gap ((the end point anion gap) – (the initial anion
gap)) >5 mmol/l.
b Signiﬁcant difference.>6 weeks and the group using LZD for >6 weeks (Supplementary
Material 3). On linear regression analysis, the anion gap increased
by 0.065 per day (R2 = 0.057), however, some patients who had LZD
use for more than 120 days had a normal anion gap. It was not an
absolute condition. There were no signiﬁcant differences according
to eGFR, diabetes, or age.
4. Discussion
Lactic acidosis is a condition characterized by >4–5 mmol/l
serum lactic acid and metabolic acidosis in arterial blood gas
analysis (ABGA). Type A lactic acidosis occurs by decreased
perfusion or oxygenation secondary to hypovolemia, cardiac
failure, and sepsis. Type B lactic acidosis occurs by impairment
of cellular metabolism secondary to diabetes mellitus (DM), drug
use, malignancy, alcoholism, and genetic disease.3 Female sex,
pregnancy, renal impairment, lipid dystrophy, and obesity are
known risk factors for lactic acidosis. Signs and symptoms of lactic
acidosis include nausea, vomiting, weight loss, hyperventilation,
and tachypnea. In severe cases, a decreased response to catechol-
amine, decreased contractility of the myocardium, impairment of
brain metabolism, and confusion can lead to death.
LZD was approved by the US Food and Drug Administration
(FDA) in 2000 for the treatment of infections caused by methicillin-
resistant S. aureus (MRSA), VRE, and mycobacterial infections. LZD
inhibits bacterial protein synthesis by binding to residues within
the 23S ribosomal RNA of the 50S large subunit of bacterial
ribosomes.4 LZD binds to mammalian ribosomes, leading to a
decrease in the activity of respiratory chain complexes containing
mitochondrial DNA-encoded subunits and a decrease in the
amount of protein of these complexes,5 due to obvious similarities
between bacterial ribosomes and mammalian cytoplasmic ribo-
somes.6 De Vriese et al. reported decreased mitochondrial
enzymatic activity in the affected tissues of a patient with LZD.
In addition, decreasing respiratory chain complex enzyme activity
of the mitochondria was also observed.7
In the present study, lactic acidosis occurred in ﬁve cases (6.8%)
in the group who used LZD. In our cases, the infections were well
controlled. No patient had liver disease or was using any other
medication that causes lactic acidosis, excluding LZD. Serum
glucose was well controlled in the three diabetic patients and the
cancer was stable in ‘probable’ case patient 1. In addition, other
possibilities including alcohol consumption, obesity, pregnancy,
and exercise were also excluded by hospitalization. None of the
patients in the group who used teicoplanin developed lactic
acidosis, which was a comparable result.
Our study has some limitations, including a relatively small
number of patients, the retrospective design, and that patients
for whom we could not obtain the anion gap were excluded.
However, ﬁve cases (including ‘probable’ cases) of 73 patients
using LZD had lactic acidosis, an incidence similar to that
reported by the Infectious Diseases Society of America (IDSA)
network (5%).
Table 5
Demographic, clinical, and laboratory characteristics of reported cases of linezolid-induced lactic acidosis
Case Age,
years
Sex Comorbidities Disease Renal
function
Liver
function
Duration of
antibiotics
Peak lactate,
mmol/l
Clinical symptoms Days to
recovery
Treatment Outcome
Apodaca and Rakita1 52 F NR Pneumonia NR NR 11 weeks 9.9 Emesis 10 Survived
Carson et al.5 35 F AIDS NR CKD NR 5 weeks 20.5 Abdominal pain,
diarrhea
NR NR
Soriano et al.8 25 M Osteosarcoma Prosthetic infection NR NR 12 weeks 5.9 Asthenia NR Survived
75 M WM CNS infection NR NR 8 weeks 2.8 Asthenia NR Survived
5 NR NR Prosthetic infection NR NR 6 weeks 4.4 Asthenia NR Survived
Bishop et al.9 NR M NR NR NR Cirrhosis 3 weeks 10 Nausea, vomiting NR Survived
Kopterides et al.10 70 M Lymphoma Pneumonia NR NR 1 week 12.5 Asymptomatic 4 Thiamine Survived
Bernard et al.11 81 M Serotonin syndrome Osteomyelitis NI AHF 3 weeks 29.1 Fever, tachycardia,
confusion
Died Died
Pea et al.12 59 M Liver transplantation Pneumonia NR Cirrhosis 1 week 8.4 Asymptomatic 3 NR
Palenzuela et al.13 49 F Bone marrow
transplantation
VRE sepsis NR NR 8 weeks 13.3 Nausea, diarrhea 5 1 month, died
74 F Anemia Prosthetic infection NR Cirrhosis 6 weeks 18.4 Nausea, vomiting,
mental change
Died Died
Vu and Walia14 36 M Metastatic cancer Soft tissue infection NR NR 1 week 13.5 NR 7 After, died
Wiener et al.17 80 F MV replacement VRE bacteremia NR NR 3 weeks 19 Tachypnea 15 Thiamine Survived
De Vriese et al.7 63 F NR Prosthetic infection AKI NR 16 days 24.5 Blindness NR Blind
Garrabou et al.15 74 F NR Prosthetic infection NR NR 7 weeks 2.9 Asthenia NR NR
83 M NR Prosthetic infection NR NR 4 weeks 4.3 Abdominal
discomfort
NR NR
25 M NR Prosthetic infection NR NR 13 weeks 5.9 None NR NR
75 M NR CNS infection NR NR 11 weeks 2.8 Anemia, asthenia NR NR
65 M NR Prosthetic infection NR NR 5 weeks 4.4 None NR NR
Thorell et al.16 13 F Sickle cell anemia Mediastinum abscess NR NR 9 weeks NR NR 7 Survived
Scotton et al.18 81 F NR Tuberculosis spondylitis NR NR 2 weeks 18.6 Emesis 4 Survived
Lee et al.19 56 F Kidney transplantation Urinary tract infection AKI NR <1 day 4.7 NR NR NR
Boutoille et al.20 48 M NR Tuberculosis NI NR 15 weeks 11.6 Abdominal pain Died Died
Ferna´ndez de Orueta et al.21 72 M SBE NR AKI NR 5 weeks 13.8 Emesis NR NR
Velez and Janech22 36 M NR Pneumonia ESRD NR 6 weeks 13.2 Abdominal pain 7 HD Survived
Cope et al.27 20 M MELAS Pneumonia NR NR 1 day 7 Tachypnea,
tachycardia
1 Survived
Su et al.23 6M M Liver transplantation VRE sepsis, pneumonia NR AHF 5 weeks 24 NR Died HD Died
6M F CDG-1A Pneumonia NR AHF 4 weeks 38 NR Died Died
16 M Cryptogenic cirrhosis urinary tract infection AKI Cirrhosis 7 day 30 NR Died Died
Contou et al.24 81 M Cryoglobulinemia Pneumonia CKD NI 4 h 16 Confusion,
tachypnea,
tachycardia
14 h Died
Carbajo et al.25 79 M BPH Prosthetic infection CKD NR 7 weeks 3.1 Malaise, asthenia,
anorexia, vomit
NR Survived
De Bus et al.26 55 F Rheumatoid arthritis Prosthetic infection NR AHF 7 weeks 12.1 Vomiting, nausea A few
days
HD 4 months, died
Miyawaki et al.28 75 M Gastric cancer Pyogenic spondylitis NI NI 10 weeks 25 Dyspnea, coma 5 HD Survived
Del Pozo et al.29 72 F Liver transplantation Nocardiosis NR NR 13 weeks 4.8 Coma NR Thiamine Survived
43 M Liver transplantation Tuberculosis AKI NR 8 weeks 7.2 Nausea, asthenia,
diarrhea
NR Thiamine Survived
AHF, acute hepatic failure; AKI, acute kidney injury; BPH, benign prostate hyperplasia; CDG-1A, congenital disorder of glycosylation type 1a; CKD, chronic kidney disease; CNS, central nervous system; ESRD, end-stage renal disease;
F, female; HD, hemodialysis; M, male; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MV, mitral valve; NI, normal; NR, not reported; SBE, subacute bacterial endocarditis; VRE, vancomycin-
resistant Enterococcus; WM, Waldenstro¨m’s macroglobulinemia.
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mitochondrial damage, therefore we speculate that the duration of
LZD use is an important risk factor for lactic acidosis. In addition,
according to the IDSA network report, a longer duration of LZD
treatment is likely to result in LZD-induced lactic acidosis. In our
study, a longer duration of treatment was likely to result in a higher
anion gap.
We searched for cases of LZD-induced lactic acidosis reported
in the English language literature in PubMed (Table 5).7–29 In the
case series, the mean duration of LZD use was 5.5 weeks;
25 patients used LZD for more than 4 weeks. Of the patients who
used LZD for less than 4 weeks (n = 12), six had other risk factors
for lactic acidosis (liver cirrhosis n = 2, pneumonia n = 1, post
liver transplantation n = 3, MELAS (mitochondrial encephalo-
myopathy, lactic acidosis, and stroke-like episodes) syndrome
n = 1, C-viral cryoglobulinemia n = 1). However, cases were
reported even in patients without these risk factors with a short
period use. Therefore, we think that a long period of use is not a
prerequisite.
No signiﬁcant difference was observed between the normal
group and the renal failure group (eGFR <50 ml/min/1.73 m2). In
the case series review (Table 5), there were four cases of chronic
renal failure (CRF), ﬁve cases of acute renal failure (ARF), and
one case of end-stage renal disease (ESRD), which is not thought
to have a signiﬁcantly higher incidence than normal renal
function. LZD is primarily metabolized by hepatic microsomal
oxidation, and approximately 30% of total metabolism occurs
in the kidney.30–32 In a pharmacokinetic study of LZD, LZD
accumulation was not common in renal impairment.32 The
kidney did not play a main role in lactic acid metabolism.
Therefore, renal failure is not thought to be a major risk factor
for LZD-induced lactic acidosis.22 However, lactic acid metabo-
lism by the kidney is nearly 30%, therefore severe renal
impairment can be attributed to LZD-induced lactic acidosis.
In clinical practice, many patients with renal impairment have
metabolic acidosis, so even relatively mild lactic acidosis can
lead to the development of fatal acidosis. Therefore, renal
impairment is not related to the incidence of LZD-induced lactic
acidosis, but can affect severity and mortality.
Diabetes itself is known as a cause of lactic acidosis. However, in
our study and case series, there were no statistically signiﬁcant
differences associated with diabetes. However, our study included
a small number of diabetes patients, and diabetic patients may
have been omitted in the case series. Further studies on this subject
are required.
LZD is metabolized mainly by the liver and more than 60% of
lactic acid is also metabolized by the liver. In a report by Palenzuela
et al.,13 the serum LZD concentration was found to be 4–6 times
higher in a patient with liver dysfunction than that in normal
patients; lactic acidosis was found in the patient with liver
dysfunction. One case series reported three patients with liver
cirrhosis and two patients with liver transplantation (Table 5).
Therefore, liver dysfunction can be considered a risk factor for LZD-
induced lactic acidosis. However, a very small number of patients
with liver dysfunction were included in our study; therefore, we
could not perform an analysis.
Many people believe that age is the most important factor,
even though there is no evidence. No clear research has yet
been reported. However, it is clear that it can occur even at a
young age.
There are few alternative antibiotics for MDR Gram-positive
bacteria and mycobacteria. Therefore, even though patients may
have the risk factors mentioned above, for some there is no other
choice of antibiotic. Considering that 6 weeks of use is an obvious
risk factor, a short period of LZD use should be considered, with
close lactic acid monitoring.If the patient has symptoms, serum lactic acid and ABGA should
be administered. Even if the patient has no symptoms, high-risk
patients should be checked regularly for serum lactic acid
concentrations. In our study, ‘possible’ case patients 4 and 5 had
no symptoms; however, we discontinued LZD through regular
checks of serum lactic acid concentrations.
The primary treatment is discontinuation of LZD; most cases
recover within 1–15 days. However, in the series presented, some
severe cases required hemodialysis, ﬁve patients had dialysis, and
three patients died (Table 5). The administration of bicarbonate to
raise the intracellular pH can be considered. However, in one
human study, bicarbonate did not improve the hemodynamic
state.33–38 In addition, in our ‘probable’ case patients 1 and 2,
bicarbonate did not improve hemodynamic stability. Other buffers
(carbicarb, dichloroacetate, tromethamine) have been studied for
the treatment of lactic acidosis. However, human studies have not
demonstrated superiority of any of the buffers.39 Renal replace-
ment therapy (RRT) has been used for the treatment of severe
acidosis. RRT is attributed to 3% of lactic acid excretion, however it
can improve acidemia and eliminate LZD.40–43 Therefore, RRT can
be an option for LZD-induced lactic acidosis. However, no large
randomized studies on survival have been reported. Another
important treatment is the correction of other risk factors of lactic
acidosis (hypoxemia, thiamine deﬁciency, other drugs). In the case
series (Table 5), two patients received infusions of thiamine,
however the effects were not clear. The prognosis of LZD-induced
lactic acidosis is poor; nine patients (26%) died in our case series
(Table 5).
The current study has several limitations. First, the relatively
small number of patients limited the statistical power of
comparisons. Second, as this was a retrospective study, there
may have been some bias. Third, we checked the serum lactic acid
levels of the LZD group regularly for the two most recent years
(n = 12; ‘probable’ cases 4 and 5); we did not check teicoplanin, and
this could have resulted in an exaggeration of the difference
between the two groups. However, if patients whose lactic acid
levels were checked regularly were excluded, comparison of the
two groups showed a difference. Fourth, most patients were not
checked for serum lactic acid and ABGA, and so anion gap was used
for the analysis. However, we excluded cases who showed other
risk factors for an increasing anion gap. Thus, we assumed that an
increasing anion gap is correlated with lactic acidosis. In addition,
we were at ﬁrst going to compare the two groups with the APACHE
II score (Acute Physiology and Chronic Health Evaluation).
However, the Glasgow coma scale score and arterial pH were
missing for many patients. Therefore, we compared other factors
included in the APACHE score (sodium, potassium, creatinine,
hematocrit, WBC count; Table 1), and there were no differences
between the two groups. Despite these limitations, the current
study represents the ﬁrst on LZD-induced lactic acidosis. Further
studies are needed.
In conclusion, LZD showed an association with treatment-
related lactic acidosis. A longer duration of LZD use (>6 weeks) was
a risk factor for metabolic acidosis. Renal impairment, age, and DM
were not obvious risk factors. Some patients with early LZD-
induced lactic acidosis have no symptoms. Therefore, even if there
are no symptoms, we suggest that serum lactate concentrations
are checked regularly, especially for those on long-term use.
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